Download Files:
Products Details
Product Description
– Tilomisole (Wy 18251) is a benzimidazothiazole experimental agent with anti-inflammatory activity. Tilomisole causes less agranulocytosis than levamisole, but retains immunomodulating capabilities. Tilomisole is orally active. Tilomisole has the potential for the research of cancer and inflammation[1][2].
Web ID
– HY-106050
Shipping
– Room temperature
Applications
– COVID-19-immunoregulation
Molecular Formula
– C17H11ClN2O2S
References
– [1]Dillman RO, et al. WY 18,251 (Tilomisole), an analog of levamisole: tolerability, and immune modulating effects in cancer patients. Mol Biother. 1992;4(1):10-14.|[2]Darwish SA, et al. New tilomisole-based benzimidazothiazole derivatives as anti-inflammatory agents: Synthesis, in vivo, in vitro evaluation, and in silico studies [published online ahead of print, 2022 Jan 29]. Bioorg Chem. 2022;120:105644.
CAS Number
– 58433-11-7
Molecular Weight
– 342.80
SMILES
– O=C(CC1=C(C2=CC=C(Cl)C=C2)N3C4=C(C=CC=C4)N=C3S1)O
Clinical Information
– No Development Reported
Research Area
– Cancer; Inflammation/Immunology
Solubility
– 10 mM in DMSO
Target
– Others
Pathway
– Others
Product type
– Reference compound
Disclaimer: All products are for research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation.
